Safety, PK and PD Study of ABX464 in Untreated HIV Patients
A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is intended to assess the safety, the tolerability, and pharmacokinetic parameters and to evaluate the effect on viral load of repeated oral administrations of ABX464 in patients infected by HIV, not previously treated for their HIV.
Two types of design are intended in this protocol: dosing every 3 days or dosing every day. The goal is to determine the best dosing regimen to reduce viral load and minimize adverse events.
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段2
联系人和位置
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Males or females, 18 to 65 years of age
- Patients infected by HIV-1 or HIV-2
- BMI between 17 and 29 kg/m².
- CD4 cell count ≥ 350 /mm3 and HIV RNA level between 5,000-500,000 copies/mL.
- Clinical laboratory tests (hematology, blood chemistry, and urinalyses) must be within normal limits, or clinically acceptable to the sponsor and principal investigator and consistent with the underlying HIV infection.
- Urine drug screen for drugs with a high potential for abuse (cocaine, opiates, amphetamines and barbiturates) and alcohol breath test must be negative.
- Females must be non lactating and either be of nonchildbearing potential (ie sterilized via hysterectomy or bilateral tubal ligation or at least one year post-menopausal) or if of child bearing potential, must be practicing effective double barrier contraceptive methods from at least two weeks prior to Day 1 until 3 months after the last dose of study medication.
- Males must practice an effective barrier method of contraception from Day 1 until 3 months days after the last dose of study medication.
- Patients must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules.
- Physical examination and ECG must be within normal limits.
- Never taken any antiretroviral agent except for a brief time, and for some reasons, the patient decided not to continue therapy (i.e. Toxicity, personal decision. None in past 30-180 days.
Exclusion Criteria:
- Individuals with a history of any significant medical disorders which requires a physician's care.
- Individuals who have a history of any clinically significant local or systemic infectious disease (other than HIV-1 or HIV-2 infection) within four weeks prior to drug administration.
- Individuals with any clinically significant laboratory abnormalities as defined as grade 2 or 3 in Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
- Individuals who are positive for hepatitis B virus and/or hepatitis C virus
- Any individual who does not comply with the requirement that he should not have used any drugs (including prescription, nonprescription, herbal, and mineral supplements) other than paracetamol for at least two weeks prior to the study nor alcohol within 48 hours prior to drug administration and for the entire study period. The use of a concomitant medications to treat an AE during the study will not be considered a protocol violation.
- Individuals who have participated in a clinical trial of an investigational drug within 90 days prior to the start of the study
- Individuals who smoke more than ten cigarettes or equivalent tobacco use per day.
- Individuals with forfeiture of freedom by an administrative or legal obligation or under guardianship
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
|
|
实验性的:ABX464
|
25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability profile of ABX464 as assessed by the change from baseline in laboratory values, in vital signs and ECG parameters at week 3 and by the number of patients with adverse events.
大体时间:Week 3
|
Number of patients with abnormal blood (hematology and biochemistry) and urinary laboratory values, abnormal vital signs and ECG parameters and the number/proportion of patients reporting any adverse event.
|
Week 3
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cmax
大体时间:week 1, week 2 and week 3
|
Maximum concentration in plasma of ABX464 and metabolite
|
week 1, week 2 and week 3
|
|
tmax
大体时间:Week 3
|
Time to maximum concentration
|
Week 3
|
|
AUC
大体时间:Week 3
|
Area under the concentration-time curve
|
Week 3
|
|
t1/2
大体时间:Week 3
|
Half-life of the ABX464 in plasma
|
Week 3
|
|
Pharmacodynamic activity as expressed by CD4 and CD8 count
大体时间:Week 3
|
CD4 and CD8 values
|
Week 3
|
|
Pharmacodynamic activity as expressed by HIV viral load
大体时间:Week 3
|
HIV viral load across time and possible relationship with PK parameters
|
Week 3
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (估计)
首次发布
研究记录更新
最后更新发布 (估计)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.